PECAM1 and neoplasm: For cell‐derived xenograft (CDX) models, ANO1 knockdown leaded to markedly lower in vivo tumor growth rate/weight at the final observation (Figure 2E), and reduced IHC staining for proliferation marker Ki67 and vascular marker CD31 in stripped xenografts (Figure 2F).